Don’t make deals with terrorists

This is why nations shouldn’t pay ransom.

“The president reacted to the Supreme Court’s judgment by initially announcing a new universal 10% levy, using a different legal framework for the latest tariffs, but then increased the global tariff rate to 15% — the legal maximum which can be in place for 150 days before congressional approval is required. 

 

“The new import duties are “effective immediately,” Trump said in a Truth Social post on Saturday. 

 

“Officials in Europe and London expressed alarm and consternation at the latest upheaval in global trade relations, saying Trump’s new tariff policy could upend trade deals signed with the U.S. last year.”

*snip*

“Do new tariffs ... not constitute a breach of the deal? Regardless, no one knows whether the US will adhere to it – or even be able to,” Lange said, adding that “clarity and legal certainty are needed before any further steps are taken.”

Trump has a decades-long history of reneging on deals. This should be a surprise to nobody.

What has made the dollar the world’s reserve currency and US Treasuries the safest haven for investment is that they’re backed by “the full faith and credit of the United States.” Trump is destroying that reputation. The Trump GOP in Congress is doing nothing to stop him.

https://www.cnbc.com/2026/02/23/trump-15percent-global-tariff-europe-eu-uk-reaction.html

Comments

Post a Comment

Popular posts from this blog

Yes, the CDC can change its mind

The Nobel Laureate economist Paul Samuelson famously acknowledged in a Meet the Press interview: “Well when events change, I change my mind. What do you do?” This observation applies to the advice from medical authorities such as the CDC and WHO during the COVID pandemic. Some members of the public are fond of pillorying these agencies for having published different guidelines at different times, as though health officials are in the business of issuing ex cathedra dogma rather than responding to incomplete and ambiguous information. Science doesn’t deal in proof, it deals with the weight of evidence. A scientific hypothesis is one that is capable of being tested and falsified by experiment. I get it. I used to teach problem-based learning to first year medical students, and they often struggled with what to do with incomplete and ambiguous information, which is what physicians in clinics do every day. Sometimes, one cannot wait for all the tests to be completed and all the data analyz...
Read more

About that Trump lawsuit

So Trump is suing Rupert Murdoch for defamation because of the release of a salacious doodle. Nothing remarkable about Donald J. Trump weaponizing the legal system against his opponents, I know. But there are some things that do bear remark here: “ . . . he's suing Rupert Murdoch personally. But you know who he's not suing? Lachlan Murdoch, who's actually the chairperson of News Corp and Fox, who's actually the decision-maker. Rupert Murdoch has no official role there anymore. He's an adviser.   “So, I thought that was revealing in a lot of ways, because it isn't just about going after the entity. It's sort of this expansion spillover, trying to send as much of a message as you possibly can. He's sort of hitting every potential lever, not just against Murdoch and that empire, but then all the other media properties in the future. It's also about sending an example.” “HAYES: Yeah. That, to me, is the point here, is that these lawsuits are not lawsuits...
Read more

I agree with RFK Jr.

Though it feels weird to say it, RFK Jr and I agree on something: curtailing direct-to-consumer marketing of pharmaceuticals. “ The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending.   Although the US is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it’s instead focusing on cutting down on the practice by adding legal and financial hurdles, according to people familiar with the plans who weren’t authorized to speak publicly on the matter.   “The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad — likely making broadcast ads much longer and prohibitively expensive — or removing the industry’s ability to d...
Read more